What is VigiBase?
VigiBase is UMC’s starting-point for the journey from data to wisdom about safer use of medicines and wise therapeutic decisions in clinical practice. It is the driving-force at the heart of the work of UMC and the WHO Programme for International Drug Monitoring (WHO PIDM). The purpose is to ensure that early signs of previously unknown medicines-related safety problems are identified as rapidly as possible.
VigiBase is the unique WHO global database of reported potential side effects of medicinal products. It is the largest database of its kind in the world, with over 30 million reports of suspected adverse effects of medicines, submitted, since 1968, by member countries of the WHO PIDM. It is continuously updated with incoming reports.
Alongside its data management and quality assurance tools, the VigiBase system is linked to medical and drug classifications such as WHODrug, MedDRA, WHO ICD, and WHO-ART. These classifications enable structured data entry, retrieval and analysis at different levels of precision and aggregation, which are vital in order to enable effective and accurate analysis.
Covering 99% of the world
UMC has developed and maintained VigiBase since 1978. Altogether, the WHO Programme members today represent close to 99% of the world’s population. Following the ten founder members of the late 1960s, around 150 countries are now actively contributing data to VigiBase.